• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab.

作者信息

Dagna Lorenzo, Corti Angelo, Langheim Silvia, Guglielmi Barbara, De Cobelli Francesco, Doglioni Claudio, Fragasso Gabriele, Sabbadini Maria Grazia, Ferrarini Marina

机构信息

Unit of Medicine and Clinical Immunology, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Via Olgettina 60-20132 Milano, Italy.

出版信息

J Clin Oncol. 2012 Oct 1;30(28):e286-90. doi: 10.1200/JCO.2012.41.9911. Epub 2012 Aug 6.

DOI:10.1200/JCO.2012.41.9911
PMID:22869874
Abstract
摘要

相似文献

1
Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab.肿瘤坏死因子α作为 Erdheim-Chester 病炎症的主要调节因子：英夫利昔单抗治疗患者的理论依据。
J Clin Oncol. 2012 Oct 1;30(28):e286-90. doi: 10.1200/JCO.2012.41.9911. Epub 2012 Aug 6.
2
TNF-α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab.厄德里希-切斯特病心包积液中的肿瘤坏死因子-α在体外可促进内皮渗漏，英夫利昔单抗可对其进行中和。
Rheumatology (Oxford). 2014 Jan;53(1):198-200. doi: 10.1093/rheumatology/ket246. Epub 2013 Jul 26.
3
Treatment of Erdheim-Chester disease with canakinumab.用卡那单抗治疗 Erdheim-Chester 病。
Rheumatology (Oxford). 2014 Dec;53(12):2312-4. doi: 10.1093/rheumatology/keu344. Epub 2014 Sep 17.
4
Erdheim-Chester disease harboring the BRAF V600E mutation.携带BRAF V600E突变的 Erdheim-Chester 病。
J Clin Oncol. 2012 Nov 10;30(32):e331-2. doi: 10.1200/JCO.2012.43.2260. Epub 2012 Sep 24.
5
Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis.三名 Erdheim-Chester 病患者中细胞因子和趋化因子网络的免疫组化证据：对发病机制的启示
Arthritis Rheum. 2006 Dec;54(12):4018-22. doi: 10.1002/art.22280.
6
Erdheim-Chester disease: multisystem involvement and management with interferon-alpha.厄尔德海姆-切斯特病：多系统受累及α干扰素治疗
Leuk Res. 2010 Jan;34(1):e21-4. doi: 10.1016/j.leukres.2009.07.026. Epub 2009 Aug 12.
7
Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib.卡那单抗治疗一名对阿那白滞素难治的进行性多系统 Erdheim-Chester 病患者失败：维莫非尼的成功应用
Rheumatology (Oxford). 2015 Oct;54(10):1932-4. doi: 10.1093/rheumatology/kev237. Epub 2015 Jul 2.
8
Interferon-alpha in cardiac Erdheim-Chester disease.α干扰素治疗心脏型 Erdheim-Chester 病
J Am Coll Cardiol. 2011 Dec 13;58(25):2695. doi: 10.1016/j.jacc.2011.03.077.
9
Erdheim-Chester disease in childhood: a challenging diagnosis and treatment.儿童期 Erdheim-Chester 病：具有挑战性的诊断与治疗
J Pediatr Hematol Oncol. 2009 Oct;31(10):782-6. doi: 10.1097/MPH.0b013e3181b76827.
10
Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease.化疗和干扰素-α治疗 Erdheim-Chester 病。
Pediatr Blood Cancer. 2010 Oct;55(4):745-7. doi: 10.1002/pbc.22636.

引用本文的文献

1
Parkinson's disease: exploring the systemic immune mechanisms through molecular investigations.帕金森病：通过分子研究探索全身免疫机制
Inflammopharmacology. 2025 Jun 23. doi: 10.1007/s10787-025-01816-9.
2
Erdheim-Chester Disease of the Breast: First Review and First Case of Isolated Severe Gynecomastia.乳腺 Erdheim-Chester 病：首例综述及首例孤立性重度男性乳房发育病例
Diagnostics (Basel). 2023 Mar 25;13(7):1239. doi: 10.3390/diagnostics13071239.
3
Case Report of Erdheim-Chester Disease Successfully Treated with Pegylated Interferon: A Single-Center Experience.
培戈干扰素成功治疗 Erdheim-Chester 病：单中心经验报告。
Cancer Res Treat. 2023 Jul;55(3):1053-1057. doi: 10.4143/crt.2022.1535. Epub 2023 Jan 19.
4
Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis.癌基因诱导造血祖细胞衰老的特征是骨髓受限性造血、慢性炎症和组织细胞增生症。
Nat Commun. 2021 Jul 27;12(1):4559. doi: 10.1038/s41467-021-24876-1.
5
The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease.微小RNA对 Erdheim-Chester 病炎症和肿瘤特征的作用
Cancers (Basel). 2020 Nov 3;12(11):3240. doi: 10.3390/cancers12113240.
6
Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy.双重BRAF/MEK阻断可恢复BRAF抑制剂单药治疗后BRAF突变型 Erdheim-Chester病患者的中枢神经系统反应。
Neurooncol Adv. 2020 Mar 3;2(1):vdaa024. doi: 10.1093/noajnl/vdaa024. eCollection 2020 Jan-Dec.
7
Erdheim-Chester disease: a rapidly evolving disease model.厄德海姆-切斯特病：一种快速演变的疾病模型。
Leukemia. 2020 Nov;34(11):2840-2857. doi: 10.1038/s41375-020-0944-4. Epub 2020 Jun 26.
8
Erdheim-Chester Disease With Extensive Pericardial Involvement: A Case Report and Systematic Review.广泛心包受累的 Erdheim-Chester 病：一例报告及系统评价
Cardiol Res. 2020 Apr;11(2):118-128. doi: 10.14740/cr1025. Epub 2020 Mar 10.
9
Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.与 Erdheim-Chester 病相关的自身免疫性疾病在使用 BRAF/MEK 抑制剂后有所改善。
Haematologica. 2019 Nov;104(11):e502-e505. doi: 10.3324/haematol.2018.214007. Epub 2019 Mar 28.
10
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease.用于 Erdheim-Chester 病患者的患者报告症状评估的量表。
Blood Adv. 2019 Apr 9;3(7):934-938. doi: 10.1182/bloodadvances.2018030502.